Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...

Bain Capital, an investment firm that has spread ... and diabetes and metabolic disease. The unit’s top-selling product is the amyotrophic lateral sclerosis drug Radicava, which accounted ...

Bain Capital is considering withdrawing its tender offer for Japanese IT firm Fuji Soft after rival U.S. private equity giant ...

Brentwood, Tenn.-based Surgery Partners received a nonbinding acquisition proposal from Bain Capital Private Equity on Jan. 27, offering to buy all outstanding shares for $25.75 per share in cash.

Bain Capital Private Equity has proposed to acquire the remaining shares of surgical facility operator Surgery Partners it ...

The provider of highly-engineered processing equipment and solutions will sell a 51% stake in the injection molding and extrusion business for $287 million.

Private equity firm Bain ... to sell because it could not fund the large-scale investment needed to boost Tanabe’s research and development capacity. Ricky Sun, a Partner at Bain Capital Life ...

Tokyo, Feb. 7 (Jiji Press)--Mitsubishi Chemical Group Corp. said Friday that it will sell subsidiary Mitsubishi Tanabe Pharma Corp. to U.S. investment firm Bain Capital LP. for about 510 billion yen.

the company entered into a definitive agreement to sell an ownership stake of approximately 51% in its Milacron injection molding and extrusion business to an affiliate of Bain Capital for $287M ...

The American investment company Bain Capital is considering the sale of Italmatch Chemicals SpA, an Italian manufacturer of specialty chemicals. This is reported in a press release from Bain Capital.